Making Markets for Vaccines
Profit is scarce in the areas that need medicines most. How to bridge the stunning gap?
Nothing spurs innovation like the promise of profits, which motivates pharmaceutical companies to spend the hundreds of millions of dollars necessary to develop a single drug. As drugmakers devote their efforts to curing diseases of aging, for which there are lucrative markets in wealthy countries, the poorest countries are forgotten. Only 10% of global spending on drug development goes toward prevention and treatment for ailments that affect 90% of the world's population. Such brutal economics have hindered the search for vaccines against HIV/AIDS, malaria and tuberculosis, which each year kill approximately 5 million people.Please click here for the full image.